Mail

Citation debate hits Cell The general issue highlighted in the post "Critics rip Cell paper"1 and many of the comments that followed is one of "selective citation," in which papers fail to include all relevant prior art. I believe that this example reached the current level of scrutiny because the complainant, Peter Lawrence, is a well-known scientist and he was willing to raise a

Written byThe Scientist
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

The general issue highlighted in the post "Critics rip Cell paper"1 and many of the comments that followed is one of "selective citation," in which papers fail to include all relevant prior art. I believe that this example reached the current level of scrutiny because the complainant, Peter Lawrence, is a well-known scientist and he was willing to raise a public fuss when he felt that his work had been overlooked in a paper published in a prominent journal.

I believe that this problem is a systemic one. Authors practice selective citation to inflate the importance of their work and to avoid contrary data that would make their "story" more complicated. Editors, especially some professional editors of high profile journals, are not sufficiently knowledgeable to choose reviewers with expertise in the specific topic addressed by the paper under review. Reviewers, who may be sticklers for the scientific validity of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies